We are live on ! Find out more
GHDX

Genomic Health, Inc.
GHDX

Delisted

GHDX was delisted on the 7th of November, 2019.

111 hedge funds and large institutions have $824M invested in Genomic Health, Inc. in 2013 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less capital invested

Capital invested by funds: $858M → $824M (-$33.9M)

3% less funds holding

Funds holding: 115111 (-4)

19% less call options, than puts

Call options by funds: $992K | Put options by funds: $1.23M

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
111
Holders Change
-4
Holders Change %
-3.48%
% of All Funds
3.6%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
6
Increased
39
Reduced
38
Closed
8
Calls
$992K
Puts
$1.23M
Net Calls
-$235K
Net Calls Change
+$3.08M

GHDX Hedge Fund Activity: Q3 2013 in Review

111 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2013, worth a combined $824M — down 3.9% from $858M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GHDX and 6 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 39 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $10M. The largest seller was Fort Washington Investment Advisors, cutting an estimated $5.3M.

  • 111 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2013, down from 115 in Q2 2013.
  • Funds reported $824M of Genomic Health, Inc. stock for Q3 2013, down 3.9% quarter-over-quarter.
  • 6 funds opened new Genomic Health, Inc. positions in Q3 2013 and 8 closed out, a net change of -2 holders.
  • The largest Genomic Health, Inc. buyer in Q3 2013 was Baillie Gifford & Co, an estimated $10M added.
  • The largest Genomic Health, Inc. seller in Q3 2013 was Fort Washington Investment Advisors, an estimated $5.3M sold.

Based on aggregated 13F filings for Q3 2013.